Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: Novel monoclonal antibody and external validation study in multiple clinical facilities

Japanese Journal of Clinical Oncology

Volumn 40, Issue 1, 2009, Pages 60-72

  Kikuta, Kazutaka ^a,b,c   Gotoh, Masahiro ^a   Kanda, Tatsuo ^d   Tochigi, Naobumi ^a,c   Shimoda, Tadakazu ^c   Hasegawa, Tadashi ^e   Katai, Hitoshi ^c   Shimada, Yasuhiro ^c   Suehara, Yoshiyuki ^f   Kawai, Akira ^c   Hirohashi, Setsuo ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Gastrointestinal stromal tumor; GIST; Pfetin; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; PFETIN; TUMOR MARKER; UNCLASSIFIED DRUG; KCTD12 PROTEIN, HUMAN; PROTEIN;

ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; WESTERN BLOTTING; ANIMAL; BLOOD; CHEMISTRY; GENETICS; IMMUNOLOGY; MIDDLE AGED; MOUSE; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION AND FORECASTING; TUMOR CELL LINE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 74949127091     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp125     Document Type: Article

References (20)

1. Joensuu H, Kindblom LG. Gastrointestinal stromal tumors-a review. Acta Orthop 2004;75:62-71.
2. Miettinen M, El-Rifai WE, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
3. Rumessen JJ, Peters S, Thuneberg L. Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon. Lab Invest 1993;68:481-95.
4. Dematteo RP, Ballman KV, Antonescu CR, Maki R, Pisters P, Demetri G, et al. Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
5. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764.
6. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
7. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
8. Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003;21:1688.
9. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005;11:638-45.
10. Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Gotoh M, et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008;14:1707.
11. Resendes BL, Kuo SF, Robertson NG, Giersch AS, Honrubia D, Ohara O, et al. Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol 2004;5:185-202.
12. Hamilton SR, Aaltonen LA, International Agency for Research on C, World Health O. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press 2000.
13. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008;135:1358-68.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
16. Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J 2005;46:258.
17. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-76.
18. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-77.
19. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-78.
20. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-79.